TABLE 2.
Patient characteristics
| Subjects | Sex | Age, years | Age at onset, years | Familial history | Epilepsy syndrome | EEG pattern | Current AEDs | Past AEDs |
|---|---|---|---|---|---|---|---|---|
| SUBJ‐1 | F | 50 | 22 | No | JAE (A, GTCS) | 3 Hz GSW, GPSW | VPA 2 × 500 mg, TPM 2 × 50 mg | CBZ, LTG, ESM, LCM, CLB, VGB, CZP |
| SUBJ‐2 | M | 9 | 8 | Yes | CAE (MS, A) | 3 Hz GSW | TPM 2 × 200 mg, VPA 2 × 300 mg, CZP 3 × 2.5 mg/ml | ESM |
| SUBJ‐3 | M | 19 | 6 | No | JAE (A, GTCS) | 3–4 Hz GPSW | LCM 200 mg, VPA 1 g | CBZ, ESM, LTG |
| SUBJ‐4 | F | 9 | 8 | No | CAE (A) | 3 Hz GSW | VPA 2 × 300 mg | ESM, LTG |
| SUBJ‐5 | F | 25 | 6 | Yes | JAE (A, GTCS, MS) | 3 Hz GSW | BRV 2 × 50 mg, CZP 3 × .5 mg, LTG 200–300 mg | ESM, LEV, VPA |
| SUBJ‐6 | F | 44 | 12 | No | JAE (A, GTCS) | 3 Hz GSW, GPSW | CZP .5 mg, LCM 300 mg, VPA 1500 mg | ESM, LEV, LTG, TPM |
| SUBJ‐7 | F | 21 | 13 | Yes | JAE (A, GTCS) | 3 Hz GSW, GPSW | CLB 3 × 10 mg, LCM 2 × 200 mg | CZP, ESM, LEV, LTG, VPA |
| SUBJ‐8 | F | 20 | 12 | No | JAE (A, GTCS) | 3‐4 Hz GSW, GPSW | LTG 2 × 300 mg, ESM 250 mg | LEV |
| SUBJ‐9 | M | 22 | 15 | Yes | JAE (A, GTCS) | 3‐4 Hz GSW, GPSW | VPA 300 mg, LTG 2 × 200 mg, ESM 2 × 10 ml/d, LCM 2 × 100 mg | LEV |
| SUBJ‐10 | M | 24 | 10 | No | JAE (A, GTCS) | 3 Hz GSW, GPSW | LTG 2 × 200 mg, VPA 1 g | CZP, ESM, LEV, OXC, TPM, PER, LCM, BRV |
| SUBJ‐11 | M | 12 | 8 | No | JME (A, GTCS) | 3 Hz GSW | VPA 2 × 300 mg | – |
| SUBJ‐12 | F | 8 | 7 | No | JAE | 3 Hz GSW | VPA 2 × 5 ml, LEV 2 × 3.5 ml | – |
Abbreviations: A, absence; AED, antiepileptic drug; BRV, brivaracetam; CAE, childhood absence epilepsy; CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; EEG, electroencephalographic; ESM, ethosuximide; F, female; GPSW, generalized polyspike waves; GSW, generalized spike waves; GTCS, generalized tonic–clonic seizures; JAE, juvenile absence epilepsy; JME, juvenile myoclonic epilepsy; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; M, male; MS, myoclonic seizures; OXC, oxcarbazepine; PER, perampanel; TPM, topiramate; VGB, vigabatrin; VPA, valproate.